ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Additional DCE Contract Concepts

November 16, 1984

FDA Approves Genetic Test For Breast Cancer Patients

January 25, 2008

Tamoxifen: No Mortality Benefit For Most “High Risk” Women

September 29, 2006

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985

Clinical Trials Renew By NCI Gets Under Way

May 3, 1985

NCAB Removes Its Restrictions On PDQ Access, Permits NCI Staff To Decide

February 7, 1986